Search clinical trials for: IBI112 dose 4

Total 10105 results

Innovent Biologics (Suzhou) Co. Ltd.

Completed

Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects

Healthy Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19

COVID-19

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis

Psoriasis

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

Psoriasis

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis

Ulcerative Colitis (UC)

China
Rutgers, The State University of New Jersey
Centers for Disease Control and Prevention

Completed

Experimentally Testing the Effectiveness of a Campus-based Bystander Intervention

Violence | Helping Behavior | Sexual Assault and Rape | Assaultive Behavior

United States
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
MicuRx
Worldwide Clinical Trials

Completed

Single Dose Escalation and Multiple Dose Escalation Trial of an Intravenous Formulation of MRX-4

Safety
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

Advanced Solid Tumors

China
Loyola University
National Cancer Institute (NCI)

Active, not recruiting

Transfer of Genetically Engineered Lymphocytes in Melanoma Patients

Melanoma

United States
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

DLBCL

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of Longer Interval of IVT IBI302 in Subjects With nAMD

Neovascular Age-related Macular Degeneration

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of IBI302 in Patients With nAMD

Neovascular Age-related Macular Degeneration

China
University of Sao Paulo General Hospital

Completed

Impact of Low Dose Fluoroscopy in Ureteroscopy

Ureteral Stone

Brazil
University of Maryland, Baltimore
Medical Technology Enterprise Consortium (MTEC)

Completed

Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)

Dengue

United States
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

China
Innovent Biologics (Suzhou) Co. Ltd.

Suspended

Evaluation of IBI302 Injection in nAMD or DME

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

China
Boehringer Ingelheim

Completed

Dose Escalation Study With 99mTC - or 186 Re-labelled Humanised Monoclonal Antibody (hMAb) BIWA 4 in Patients With Head and Neck Cancer

Head and Neck Neoplasms
Third Affiliated Hospital, Sun Yat-Sen University

Unknown

Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation

Hepatocellular Carcinoma

China
Taiho Pharmaceutical Co., Ltd.

Recruiting

A Study of TAS3731 in Healthy Adults

Healthy Adult Males

Japan
Aronora, Inc.

Completed

Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects

Thrombosis

United States
Pfizer

Completed

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

Healthy Participants

United States, Belgium
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)

Gout Arthritis

China
Anagram Therapeutics, Inc.

Recruiting

Phase 1 Study to Assess Safety and Efficacy of ANG003

Exocrine Pancreatic Insufficiency

United States
GlaxoSmithKline

Completed

The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury

Lung Injury, Acute

United States, Canada
MedImmune LLC

Completed

Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884

Healthy Volunteers

United States
GlaxoSmithKline

Completed

Efficacy and Safety Study in Subjects With Asthma

Asthma

United States
MedImmune LLC

Completed

A Study to Assess the Safety of MEDI7836 in Healthy Adults.

Healthy Adults

United Kingdom
Basilea Pharmaceutica

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Fungal Infection

Netherlands
Pennington Biomedical Research Center
National Center for Complementary and Integrative Health (NCCIH); Office of...

Completed

Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.) (RT2)

Diabetes Prevention

United States
Epeius Biotechnologies

Terminated

Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer

Pancreatic Cancer

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients

Neovascular Age-related Macular Degeneration

China
CK Regeon Inc.

Completed

Safety, Tolerability, and Pharmacokinetic Evaluations of CKR-051 After Transdermal Administration in Healthy Male Subjects

Healthy

Korea, Republic of
Bioxodes S.A.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ir-CPI in Healthy Male Subjects

Healthy

Belgium
Institute of Medical Biology, Chinese Academy of...
Guangxi Center for Disease Control and Prevention

Completed

Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV

Poliomyelitis

China
Novo Nordisk A/S

Completed

A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People

Type 2 Diabetes | Healthy Volunteers

United States, Canada
Aronora, Inc.

Completed

Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects

Thrombosis

United States
Pulmongene Ltd.

Completed

A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015

Idiopathic Pulmonary Fibrosis

Australia
WinSanTor, Inc

Completed

A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy

Peripheral Neuropathy | Painful Diabetic Neuropathy | Diabetic Neuropathies, Painful

Canada
Taiho Pharmaceutical Co., Ltd.

Recruiting

A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria

Japan
M.D. Anderson Cancer Center

Recruiting

A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma

Lymphoma

United States
Edgewise Therapeutics, Inc.

Recruiting

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) (LYNX)

Duchenne Muscular Dystrophy

United States
University of Chicago

Recruiting

Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

Lymphoma | Hodgkin Lymphoma | Non-hodgkin Lymphoma

United States
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia

Hyperuricemia
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)

Esophageal Squamous Cell Carcinoma (ESCC) | PD-1 Inhibitors

China
BioNTech SE
Pfizer

Withdrawn

A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children

COVID-19
Bellicum Pharmaceuticals

Active, not recruiting

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia

United States
Italian Sarcoma Group
Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna

Withdrawn

Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment. (CAST)

Sarcoma

Italy
Kyowa Kirin Korea Co., Ltd.

Recruiting

Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea Patients

Hyperphosphatemia

Korea, Republic of

3

Subscribe